CCM
PCRX icon

Century Capital Management’s Pacira BioSciences PCRX Stock Holding History

Century Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-394,330
Closed -$19M – 155
2013
Q3 		$19M Buy
+394,330
New +$14.4M 0.79% 48

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Century Capital Management's PCRX Position: Q4 2013 in Review

Century Capital Management sold out of Pacira BioSciences (PCRX) in Q4 2013, closing a stake of 394,330 shares — an estimated $19M sold.

Century Capital Management first reported a position in PCRX in Q3 2013 and held it in 1 quarter. The position peaked at $19M in Q3 2013. 132 funds tracked by Wall St. Rank hold PCRX as of Q4 2013.

  • Century Capital Management reported no remaining Pacira BioSciences position as of Q4 2013 after selling out during the quarter.
  • Century Capital Management sold 394,330 Pacira BioSciences shares in Q4 2013, an estimated $19M.
  • Century Capital Management first reported a position in Pacira BioSciences in Q3 2013 and held it in 1 quarter.
  • Century Capital Management's Pacira BioSciences position peaked at $19M in Q3 2013.
  • 132 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2013.

Based on Century Capital Management's 13F filing for Q4 2013, filed 10 Feb 2014.